



**Ain Shams University.
Faculty of Women for Arts,
Science and Education,
Zoology Department**

Treatment of cryptosporidiosis using *Nigella sativa* (El Baraka seed oil) conjugated with Chitosan nanoparticles.

**A Thesis submitted
In partial fulfillment for the requirement of PhD degree of
Science**

By

Walaa Ahmed Hussein Mohamed Hassan

Assistant lecturer of Parasitology, Zoology Department
Faculty of Women for Arts, Science & Education
Ain-Shams University

Supervisors

- | | |
|---|--|
| 1- Prof. Dr./ Eglal A. Koura | Professor of Parasitology and Protozoology,
Zoology Department, Girls college,
Ain -Shams University. (El marhouma) |
| 2 -Prof. Dr./ Ibrahim R. Shalash | Professor of Parasitology, Immunology and
Evaluation of Drugs Department,
Theodore Bilhariz Research Institute. |
| 3- Prof. Dr./ Olfat A. Hammam | Professor and Head of Pathology Department
Theodore Bilhariz Research Institute. |
| 4- Dr./ Hanan M. Ismail | Lecturer of Parasitology, Zoology Department,
Girls college, Ain -Shams University. |

2019

TABLE OF CONTENTS

Title	Page
LIST OF ABBREVIATIONS	VIII
LIST OF TABLES	XII
LIST OF FIGURES	XIV
ABSTRACT	XIX
CHAPTER I: INTRODUCTION	1
Aim of the work	5
CHAPTER II: REVIEW OF LITERATURE	6-37
1. Historical Background	6
2. Disease	7
3. Epidemiology	14
4. The life cycle	16
5. Symptoms	20
6. Diagnosis	22
6.1. Microscopic examination (the acid-fast staining technique)	23
6.2. Polymerase Chain Reaction (PCR)	24
6.3. Immunochromatographic assay	25
7. Treatment	26
7.1. Antibiotic drugs	28
a. Nitazoxanide	28
b. Nitazoxanide combination with other drugs	29
c. Paromomycin	30
d. Spiramycin	31

e. Rifamycins	31
f. Azithromycin	32
g. Albendazole	32
7.2. Natural product	33
a. <i>Nigella sativa</i> (Kavangi)_	33
b. <i>Allium sativum</i> (Garlic)	34
c. <i>Curcuma longa</i> (Curcumin)	34
d. <i>Phoenix dactylifera</i> (Date palms)	35
7.3. Immunotherapy	36
CHAPTER III: MATERIAL AND METHODS	38-56
1. Experimental animals	38
1.1. Animal infection	38
1.2. Immune suppression of the mice	38
2. Parasite	39
2.1. Isolation of <i>Cryptosporidium</i> oocysts from faeces of infected calves	39
3. Drugs	41
3.1. Nitazoxanide	41
3.2. <i>Nigella sativa</i> (El Baraka seed oil)	41
3.3. Chitosan	41
3.4. Nanoparticles	42
• Nanochitosan	42
• The preparation of Nanochitosan	42
<u>Materials</u>	42
<u>Procedure</u>	42
4. Experimental design	43
• Group I	43
• Group II	44
• Group III	44
5. Parasitological examination	45

5.1. Collection of faecal samples	45
5.2. Microscopic examination of faecal sample	45
• Ziehl-Neelsen method for acid-fast staining	45
(A). Carbol fuchsin stain	45
<u>Materials</u>	45
<u>Procedure</u>	46
(B). Decolorizing solvent	45
<u>Materials</u>	45
<u>Procedure</u>	46
(C). Methylene blue	46
<u>Materials</u>	46
<u>Procedure</u>	46
6. Duodenal examination	46
7. Animal scarification	47
8. Blood Sample	47
9. Histopathological examination	47
9.1. Embedding	47
9.2. Sectioning	47
9.3. Staining	48
(A) Hematoxylin and Eosin stain (H&E)	48
<u>Materials</u>	48
<u>Procedure</u>	48
(B) Modified Ziehl-Neelsen	48
<u>Materials</u>	48
<u>Procedure</u>	48
(C). Massons Trichrome stain (MT)	49
<u>Materials</u>	49
<u>Procedure</u>	49
(D) Periodic Acid stain (PAS)	50
<u>Materials</u>	50
<u>Procedure</u>	50
9.4. Analysis of histopathological sections	50

10.Immunological studies (serological diagnosis)	50
10.1. Determination of IgM or IgG antibodies	50
<u>Materials</u>	51
<u>Procedure</u>	51
11. Evaluation of toxic effects of nanoparticles	52
11.1. Measurement of Glutathione (GSH)	52
<u>Materials</u>	53
<u>Procedure</u>	53
11.2. Measurement of Lipid Peroxide (Malondialdehyde)	54
<u>Materials</u>	54
<u>Procedure</u>	55
12.Statistical Analysis	55
 CHAPTER IV: RESULTS	 57-138
 1. Parasitological results	 57
1.1.Parasitological results of faecal examination	57
• After twenty days post infection (seven days of treatment)	57
• After twenty three days post infection (ten days of treatment)	59
• After twenty seven days post infection (fourteen days of treatment)	65
• After thirty days post infection (seventeen days of treatment)	66
1.2.Parasitological results of duodenal examination	69
• Duodenal examination results on 18 days post infection	69
• Duodenal examination results on 30 days post infection (seventeen days of treatment)	76
2.Histopathological results	78

2.1. Small intestine	78
•Histological results of control groups A (-ve group) for immunocompetent and immunosuppressed groups	78
•Histopathological results of immunocompetent group B1 (Infected group)	79
•Histopathological results of group C1 (Immunosuppressed infected)	81
•Histopathological results of immunocompetent group B2 (infected treated with nitazoxanide NTZ)	83
•Histopathological results of group C2 (Immunosuppressed infected treated with NTZ)	84
•Histopathological results of group B3 (Infected treated with <i>Nigella sativa</i> (Baraka))	86
•Histopathological results of group C3 (Immunosuppressed infected treated with Baraka)	87
•Histopathological results of group B4 (Infected treated with chitosan nanoparticles)	89
•Histopathological results of group C4 (Immunosuppressed infected treated with chitosan nanoparticles)	90
•Histopathological results of group B5 (Infected treated with Baraka and chitosan nanoparticles)	92
•Histopathological results of group C5 (Immunosuppressed infected treated with Baraka and chitosan nanoparticles)	93
2.2. Liver	95
•Histological results of groups A (control groups) for immunocompetent and immunosuppressed groups	95
•Histopathological results of group B1 (Infected group) and group C1 (Immunosuppressed)	96
•Histopathological liver results of group B2 (Infected treated with NTZ) and group C2 (Immunosuppressed)	99
•Histopathological liver results of group B3 (Infected treated with Baraka) and group C3 (Immunosuppressed)	100

•Histopathological liver results of group B4 (Infected treated with chitosan nanoparticles) and group C4 (Immunosuppressed)	102
•Histopathological liver results of group B5 (Infected treated with Baraka and chitosan nanoparticles) and group C5(Immunosuppressed)	103
2.3. Kidney	105
•Histological results of groups A (control groups) for immunocompetent and immunosuppressed groups	105
•Histopathological results of group B1 (Infected group) and group C1 (Immunosuppressed)	105
•Histopathological results of group B2 (Infected treated with NTZ)	107
•Histopathological results of group C2 (Immunosuppressed infected treated with NTZ)	108
•Histopathological results of groups B3,B4,C3 and C4 (Infected treated with Baraka or chitosan nanoparticles for immunocompetent and immunosuppressed mice	109
•Histopathological results of group B5 (Infected treated with Baraka and chitosan nanoparticles) and group C5 (Immunosuppressed)	112
3. 3. Measurement of Immunological parameters in serum level	114
3.1. Immunoglobulin M (IgM)	114
3.2. Immunoglobulin G (IgG)	118
4. Evaluation of toxic effects of nanoparticles	122
4.1. Measurement of glutathione (GSH)	122
A. Hepatic glutathione level	123
A.1. Hepatic glutathione in immunocompetent groups	123
A.2. Hepatic glutathione in immunosuppressed groups	125
B. Renal glutathione level	127
B.1. Renal glutathione in immunocompetent groups	127

B.2. Renal glutathione in immunosuppressed groups	129
4.2. Measurement of Malondialdehyde (MDA)	131
A. Hepatic Malondialdehyde level	131
A.1. Hepatic Malondialdehyde in immunocompetent mice	131
A.2. Hepatic Malondialdehyde in immunosuppressed mice	133
B. Renal Malondialdehyde level	135
B.1. Renal Malondialdehyde in immunocompetent mice	135
B.2. Renal Malondialdehyde in immunosuppressed mice	137
CHAPTER V: DISCUSSION	139-160
CHAPTER VI: SUMMARY AND CONCLUSIONS	161-166
CHAPTER VII: REFERENCES	167-213
CHAPTER VIII: ARABIC SUMMARY	

LIST OF ABBREVIATIONS

AE	The encapsulation efficiency.
AIDS	Acquired immunodeficiency syndrome.
CD4	Cluster designation 4.
CL	Cutaneous leishmaniasis.
cm	centimetre (unit of length).
CS	Chitosan.
CS NPs	Chitosan nanoparticles.
CSO	Chitosan oligosaccharide.
DD	Degree of deacetylation.
DFA	Direct fluorescent-antibody.
DNA	Deoxyribonucleic acid.
DP	Degree of polymerization.
DPX	Distyrene Plasticizer Xylene.
DTNB	5,5dithiobis (2-nitrobenzoic acid).
EIAs	Antigen-based enzyme immunoassays.
ELISA	Enzyme- linked immunosorbent assay.
EU	European Union.
FDA	American Food and Drug Association.
GSH	Glutathione.

HAART	Active anti-retroviral therapy.
HBC	Hyperimmune bovine colostrums.
HIV	<i>Human immunodeficiency virus.</i>
HRP	Horse-radish peroxidase enzyme.
IFAT	Immunofluorescent-antibody test.
IgG	Immunoglobulin G.
IgM	Immunoglobulin M.
IMS	Immunomagnetic separation.
IU/mL	International Units Per Millilitre.
kDa	Kilo Dalton.
Kg	Kilo gram.
L	Litre.
LC	Loading capacity.
Mm	Micro meter.
MDA	Malondialdehyde.
mg	Milligram.
ml	Milliliters.
mmol/g	Millimol per gram.
MT	Massons Trichrome stain.
MW	Molecular weight.

nm	Nanometer.
NPs	Nanoparticles.
NSO	<i>Nigella sativa</i> oil.
NTZ	Nitazoxanide.
O.D.	Optical Density.
PAS	Periodic Acid stain.
PBS	Phosphate-buffered saline.
PCR	<i>Polymerase</i> chain reaction.
pg/ml	Picograms per milliliter.
PH	Power of hydrogen.
PI	Post infection.
P-value	The degree of significance.
PVM	Parasitophorous vacuole membrane.
PZQ	Praziquantel.
rpm	Revolutions per minute .
SBSC	Schistosome Biological Supply Centre.
SBSP	Schistosome biological supply program.
SCID	Severe combined immunodeficiency.
SD	Standard deviation.
SPSS	Statistical Package For Social Sciences.

TBA	Thaiobarbituric acid.
TBRI	Theodor Bilharz Research Institute.
TCL	Trichloroacetic acid.
TPP	Sodium Tripolyphosphate.
UK	United Kingdom.
WHO	World Health Organization.
X	Mean value.

LIST OF TABLES

Table No.	Title	Page No.
Table (1)	Mean and standard deviation of parasitological examination of immunocompetent groups ($X \pm SD$).	61
Table (2)	The percentage of reduction of parasitological examination of immunocompetent groups.	62
Table (3)	Mean and standard deviation of parasitological experiment of immunosuppressed groups ($X \pm SD$).	63
Table (4)	The percentage of reduction of parasitological examination of immunosuppressed groups.	64
Table (5)	Mean and standard deviation ($X \pm SD$) of duodenal examination of immunocompetent groups.	70
Table (6)	The percentage of reduction of duodenal examination of immunocompetent groups.	72
Table (7)	Mean and standard deviation ($X \pm SD$) of duodenal examination of immunosuppressed groups.	73
Table (8)	The percentage of reduction of duodenal examination data of immunosuppressed groups.	75
Table (9)	Mean and standard deviation of Immunoglobulin M (IgM) of immunocompetent groups ($X \pm SD$).	115
Table (10)	Mean and standard deviation of immunoglobulin M (IgM) of immunosuppressed groups ($X \pm SD$).	117
Table (11)	Mean and standard deviation of Immunoglobulin G (IgG) of immunocompetent groups ($X \pm SD$).	119

Table (12)	Mean and standard deviation of immunoglobulin G (IgG) of immunosuppressed groups ($X \pm SD$).	121
Table (13)	Mean and standard deviation of hepatic glutathione of immunocompetent groups ($X \pm SD$).	124
Table (14)	Mean and standard deviation of hepatic glutathione of immunosuppressed groups ($X \pm SD$).	126
Table (15)	Mean and standard deviation of renal glutathione of immunocompetent groups ($X \pm SD$).	128
Table (16)	Mean and standard deviation of renal glutathione of immunosuppressed groups ($X \pm SD$).	130
Table (17)	Mean and standard deviation of hepatic Malondialdehyde of immunocompetent groups ($X \pm SD$).	132
Table (18)	Mean and standard deviation of hepatic Malondialdehyde of immunosuppressed groups ($X \pm SD$).	134
Table (19)	Mean and standard deviation of renal Malondialdehyde of immunocompetent groups ($X \pm SD$).	136
Table (20)	Mean and standard deviation of renal Malondialdehyde of immunosuppressed groups ($X \pm SD$).	137

LIST OF FIGURES

Figure No.	Title	Page No.
Fig (1)	Life cycle of <i>Cryptosporidium</i> .	19
Fig (2)	Lateral flow test for the detection of <i>Cryptosporidium</i> in stool specimens.	25
Fig (3)	The percentage of reduction of parasitological examination of immunocompetent groups.	67
Fig(4)	The percentage of reduction of parasitological examination of immunosuppressed groups.	68
Fig (5)	Immunosuppressed infected group (C1) developing A&B: oedema (Red arrows) C&D: lesions (Yellow arrows).	69
Fig (6)	Mean and standard deviation ($X \pm SD$) of duodenal examination of immunocompetent groups.	71
Fig (7)	The percentage of reduction of duodenal examination of immunocompetent groups.	72
Fig (8)	Mean and standard deviation ($X \pm SD$) of duodenal examination of immunosuppressed groups.	74
Fig (9)	The percentage of reduction of duodenal examination data of immunosuppressed groups.	75
Fig (10)	Section of small intestine from normal control group. (H&E,x100,x200).	78
Fig (11)	Section of small intestine from normal control group (H&E, Oil, x1000)	79
Fig (12)	Sections of small intestine of infected animal (H&E,x200).	80
Fig (13 and 14)	Sections of small intestine of infected animal (H&E,x1000).	80-81
Fig (15)	Sections of small intestine of immunosuppressed infected animal (H&E, x200,x400).	82
Fig (16)	Sections of small intestine of immunosuppressed infected animal (H&E,x1000).	82